Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-6000a in Advanced Renal Cell Carcinoma and Ovarian Tumors
NCT04707248Phase 1Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of raludotatug deruxtecan in renal cell carcinoma (RCC) and ovarian cancer (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-limiting toxicities, Adverse Events and 1 more. Started Dec 2020; status: active, not recruiting.
02
Drugs
raludotatug deruxtecan
03
Conditions
renal cell carcinoma (RCC)ovarian cancer
Beyond the preview
Go deeper on NCT04707248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04707248.